febuxostat has been researched along with Kidney Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Deng, W; Huang, Q; Huang, Y; Huang, Z; Lee, PY; Li, T; Zheng, S | 1 |
| He, Z; Li, M; Ma, G; Teng, W; Xia, Z; Zhai, X | 1 |
| Abdel-Wahab, BA; El-Shoura, EAM; Shafiuddin Habeeb, M; Zafaar, D | 1 |
| Abe, T; Ito, S; Kikuchi, K; Kudo, M; Maeda, Y; Matsuhashi, T; Mishima, E; Mori, T; Nakajima, Y; Oikawa, Y; Sohara, E; Suzuki, T; Toyohara, T; Uchida, S | 1 |
| Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M | 1 |
| Alqahtani, A; Balakumar, P; Dhanaraj, SA; Khan, NA; Mahadevan, N | 1 |
| Abu-Risha, SE; Elsisi, AEE; Shalaby, MF; Sokar, SS | 1 |
| Cleveland, JD; Singh, JA | 1 |
| Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Saag, K; Whelton, A | 1 |
| Lu, L; Wang, Y; Xia, A; Zhang, S; Zhang, Y; Zhu, J | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R | 1 |
| Hibi, C; Hirata, K; Hisamichi, M; Hoshino, S; Kamijo-Ikemori, A; Kimura, K; Murase, T; Nakamura, T; Oikawa, T; Shibagaki, Y; Sugaya, T | 1 |
| Keenan, RT; Pillinger, MH | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Cohen, MG | 1 |
| Inoue, K; Isaka, Y; Kaimori, J; Kawada, N; Matsui, I; Moriyama, T; Omori, H; Rakugi, H; Takabatake, Y; Ueda, Y; Yamamoto, R | 1 |
| Hoshide, S; Hosoya, T; Ishikawa, T; Komoriya, K; Kubo, J; Ohno, I; Takahashi, Y; Tsuchimoto, M | 1 |
3 review(s) available for febuxostat and Kidney Diseases
| Article | Year |
|---|---|
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppressants; Humans; Hyperuricemia; Inflammation Mediators; Kidney; Kidney Diseases; Oxidative Stress; Signal Transduction; Uric Acid | 2020 |
Therapeutic approaches to chronic hyperuricemia and gout.
Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase | 2014 |
Febuxostat: a new agent for lowering serum urate.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Liver Diseases; Thiazoles | 2009 |
5 trial(s) available for febuxostat and Kidney Diseases
| Article | Year |
|---|---|
Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Topics: Combined Modality Therapy; Contrast Media; Coronary Angiography; Coronary Disease; Creatinine; Febuxostat; Fluid Therapy; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Lipocalin-2; Percutaneous Coronary Intervention; Treatment Outcome; Uric Acid | 2022 |
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Topics: Aged; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Febuxostat; Female; Gastrointestinal Diseases; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Middle Aged; Treatment Outcome | 2018 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Prospective Studies; Uric Acid | 2019 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Female; Humans; Kidney; Kidney Diseases; Male; Renal Insufficiency; Thiazoles; Time Factors; Xanthine Oxidase | 2004 |
10 other study(ies) available for febuxostat and Kidney Diseases
| Article | Year |
|---|---|
Clinical characteristics of juvenile gout and treatment response to febuxostat.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Treatment Outcome | 2022 |
Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3/TLR4, Sirt-1/NF-κB/TGF-β signaling Pathways, and miR-23b-3p, miR-181a-5b expression.
Topics: Animals; Arsenic Trioxide; Febuxostat; Kidney; Kidney Diseases; MicroRNAs; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Signal Transduction; Toll-Like Receptor 4; Transforming Growth Factor beta | 2023 |
HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthine Phosphoribosyltransferase; Kidney Calculi; Kidney Diseases; Male; Mutation, Missense; Treatment Outcome; Young Adult | 2020 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseases; Kidney Function Tests; Male; Myocardium; Nephrectomy; Oxidative Stress; Oxonic Acid; Protective Agents; Rats, Sprague-Dawley; Xanthine Oxidase | 2020 |
Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-κB and MCP1.
Topics: Animals; Anti-Bacterial Agents; Antidepressive Agents; Chemokine CCL2; Drug Synergism; Febuxostat; Gentamicins; Gout Suppressants; Kidney Diseases; Male; Mirtazapine; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-kappa B; Rats | 2021 |
Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Allopurinol; Comparative Effectiveness Research; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Kidney Diseases; Male; Medicare; Propensity Score; Proportional Hazards Models; Retrospective Studies; United States | 2017 |
Febuxostat inhibits TGF‑β1‑induced epithelial‑mesenchymal transition via downregulation of USAG‑1 expression in Madin‑Darby canine kidney cells in vitro.
Topics: Adaptor Proteins, Signal Transducing; Animals; Dogs; Epithelial-Mesenchymal Transition; Febuxostat; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Diseases; Madin Darby Canine Kidney Cells; Proteins; Transforming Growth Factor beta1 | 2019 |
Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
Topics: Adenine; Animals; Biomarkers; Fatty Acid-Binding Proteins; Febuxostat; Kidney; Kidney Diseases; Male; Mice; Mice, Transgenic; Nitriles; Pyridines; Xanthine Dehydrogenase | 2016 |
Treatment of gout.
Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Patient Compliance; Practice Guidelines as Topic; Prednisolone; Renal Dialysis; Thiazoles; Uric Acid | 2011 |
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Topics: Animals; Cell Movement; Cytokines; Disease Models, Animal; Febuxostat; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Nephritis, Interstitial; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles; Transforming Growth Factor beta; Ureteral Obstruction; Xanthine Oxidase | 2012 |